Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$312.72
-1.7%
$278.57
$211.43
$343.12
$8.52B1.06486,571 shs521,587 shs
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$4.85
$4.47
$3.41
$4.93
$242.62M1.097,393 shsN/A
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Don't wait for the SpaceX IPO Cover

The space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
+4.24%+10.75%+13.88%+14.25%+39.14%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.00%0.00%0.00%0.00%+12.53%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$312.72
-1.7%
$278.57
$211.43
$343.12
$8.52B1.06486,571 shs521,587 shs
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$4.85
$4.47
$3.41
$4.93
$242.62M1.097,393 shsN/A
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Don't wait for the SpaceX IPO Cover

The space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
+4.24%+10.75%+13.88%+14.25%+39.14%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.00%0.00%0.00%0.00%+12.53%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.00
Hold$303.33-3.00% Downside
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
2.00
Hold$7.0044.33% Upside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BIO, MOR, MDG1, and GNFT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2026
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Initiated CoverageOutperform$320.00
5/14/2026
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UpgradeModerate Buy
5/6/2026
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
DowngradeSell (D+)Sell (D)
5/1/2026
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Lower Price TargetEqual Weight$320.00 ➝ $290.00
4/7/2026
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
DowngradeBuyNeutral$375.00 ➝ $300.00
(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.58B3.24$9.85 per share31.75$256.01 per share1.22
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$41.52M5.84$0.07 per share69.34$1.50 per share3.23
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$759.90M$6.0751.5233.63N/A6.52%3.56%2.49%7/30/2026 (Estimated)
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$1.63MN/AN/AN/AN/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A

Latest BIO, MOR, MDG1, and GNFT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2026Q1 2026
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$1.97$1.89-$0.08-$19.55$589.91 million$592.10 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.12
3.21
2.37
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.09
3.74
3.74
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
2.24%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%

Insider Ownership

CompanyInsider Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
30.34%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
4.20%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
7,45026.76 million18.64 millionOptionable
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
12050.03 million47.92 millionNot Optionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable

Recent News About These Companies

Patent case unblocks antibody businesses
Novartis Drug Ianalumab Succeeds in Second Indication
MorphoSys takeover delivers phase 3 win for Novartis
Novartis to shut MorphSys sites amid pelabresib delay
Novartis sheds MorphoSys staff, sites after pelabresib delay
Novartis shutters MorphoSys sites, lays off staff
Novartis raises mid-term sales guidance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bio-Rad Laboratories stock logo

Bio-Rad Laboratories NYSE:BIO

$312.72 -5.50 (-1.73%)
Closing price 03:59 PM Eastern
Extended Trading
$312.24 -0.49 (-0.16%)
As of 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

GENFIT stock logo

GENFIT NASDAQ:GNFT

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 05/28/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.